|
1. Biologie
|
|
|
|
Why cancer is (still) more than just ‘bad luck’ [Cancer Research UK]
|
|
|
|
|
|
There’s
evidence that both stem cell biology and our environment and behaviours
affect our chances of developing cancer, but which plays the more
important role? Until now, the two sides have failed to do one thing;
look at the biology of how the two factors – DNA damage and stem cell
division – combine in living cells.
|
|
|
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
|
3.1 Tabac
|
|
|
Cash may convince some smokers to quit [Reuters]
|
|
|
|
|
|
To
test the power of money to combat addiction, researchers in Switzerland
offered about 800 low-income smokers pamphlets and online cessation
guides. Half of them were also eligible to receive as much as $1,650 if a
series of six lab tests verified that they stopped smoking.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
Oxygen can impair cancer immunotherapy in mice [NIH]
|
|
|
|
|
|
The
researchers discovered that T cells, a type of immune cell, contain a
group of oxygen-sensing proteins which act to limit inflammation within
the lungs. This new research shows, however, that oxygen also suppresses
the anticancer activity of T cells, thereby permitting cancer cells
that have spread to the lungs to escape immune attack and establish
metastatic colonies.
|
|
|
|
|
|
|
Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo [Reuters]
|
|
|
|
|
|
A
survey of 79 U.S. and European oncologists, published last week by
investment services firm AllianceBernstein, found that 57 percent of
respondents anticipated using more Keytruda as a result of the latest
trial results, and 70 percent said they will be more likely to order
PDL1 testing for patients.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.4 Traitements - Economie
|
|
|
Thinking straight about orphan drugs, Part 2. [The Incidental Economist]
|
|
|
|
|
|
That
pricing power helps explain why the median price of an orphan drug is a
jaw-dropping $100,000 per year. For a market of 50,000 patients—well
under the 200,000 cap for orphan designation—total revenue for a
median-priced drug would be $5 billion per year. Yes, you read that
right: that’s billion with a b.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.11 Patients
|
|
|
Well: More Life to Be Lived [NY Times]
|
|
|
|
|
|
Treatment
goals shift over time as our performance status — the measure of how
well we can carry on everyday activities — declines. It strikes me that
cancer patients recurrently have to evaluate our condition in order to
reassess our aspirations and priorities.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Go forth and replicate! [Nature]
|
|
|
|
|
|
To
make replication studies more useful, researchers must make more of
them, funders must encourage them and journals must publish them.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|